Silent rhinovirus (RV) infection is prevalent in nasal tissues and is associated with distinct immune responses in those with and without chronic rhinosinusitis with nasal polyps (CRSwNP). These were ...
Mepolizumab significantly improved outcomes in patients with CRSwNP who had 1 or more previous surgeries for nasal polyps.
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its ...
Already billed as a potential blockbuster, Amgen and AstraZeneca’s Tezspire has turned in strong clinical data in chronic ...
The U.S. Food and Drug Administration (FDA) has accepted GlaxoSmithKlines (NYSE:GSK) biologics license application for ...
In patients with CRSwNP, AEs included headache; injection site reactions; arthralgia; upper abdominal pain; and dizziness. For those with IgE-mediated food allergies, the most common AEs were ...
We closed 2024 and started 2025 with strong continued momentum, marked by the successful completion of enrollment in our Phase 2 clinical ...
In the SWIFT and ANCHOR trials, depemokimab demonstrated statistically significant reductions in nasal polyp size, ...
Research and development expenses were $21.8 million for the quarter ended December 31, 2024, compared to $11.6 million for ...
“Simultaneous regulatory submissions for 2 indications highlight our confidence in depemokimab to help reduce the burden of both asthma and CRSwNP for patients and health systems,” said Kaivan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback